Becton, Dickinson and Company $BDX Shares Acquired by Retirement Systems of Alabama

Retirement Systems of Alabama increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 14.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 66,211 shares of the medical instruments supplier’s stock after acquiring an additional 8,327 shares during the quarter. Retirement Systems of Alabama’s holdings in Becton, Dickinson and Company were worth $11,852,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. TD Waterhouse Canada Inc. boosted its stake in shares of Becton, Dickinson and Company by 17.1% in the second quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock valued at $14,715,000 after buying an additional 14,077 shares during the period. Northside Capital Management LLC grew its position in Becton, Dickinson and Company by 18.3% during the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after buying an additional 9,494 shares in the last quarter. Capital Analysts LLC increased its stake in Becton, Dickinson and Company by 7.5% during the 2nd quarter. Capital Analysts LLC now owns 83,601 shares of the medical instruments supplier’s stock worth $12,651,000 after acquiring an additional 5,828 shares during the period. NewEdge Advisors LLC increased its stake in Becton, Dickinson and Company by 35.0% during the 1st quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock worth $6,923,000 after acquiring an additional 11,414 shares during the period. Finally, Beverly Hills Private Wealth LLC acquired a new position in Becton, Dickinson and Company in the 2nd quarter valued at $3,353,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,993 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $23,134,230. This represents a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 3,310 shares of company stock worth $688,650. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $217.95 on Monday. The company has a current ratio of 0.87, a quick ratio of 0.54 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $60.05 billion, a price-to-earnings ratio of 52.64, a P/E/G ratio of 3.65 and a beta of 0.22. The firm’s 50 day simple moving average is $190.90 and its 200 day simple moving average is $170.56. Becton, Dickinson and Company has a 1 year low of $140.11 and a 1 year high of $219.78.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, beating the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.11 billion. During the same period in the previous year, the business earned $3.96 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. As a group, research analysts expect that Becton, Dickinson and Company will post 13.21 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a share repurchase program on Thursday, November 5th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 3.6% of its shares through open market purchases. Share repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be paid a $1.06 dividend. This represents a $4.24 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio is 101.45%.

Analysts Set New Price Targets

BDX has been the subject of a number of recent analyst reports. Royal Bank Of Canada upped their target price on Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a research report on Friday, November 6th. TD Cowen increased their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Bank of America raised their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Monday, August 31st. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, Zacks Research raised Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $197.47.

Read Our Latest Analysis on BDX

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Further Reading

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.